Clinical features and outcome of the 48 patients with nasal NK/T-cell lymphomas and of the subgroup of 39 patients evaluable for expression of PI9
| Clinical features . | Entire group . | Subgroup . |
|---|---|---|
| No. of patients | 48 | 39 |
| No. male/no. female | 29/19 | 27/12 |
| Median age, y (range) | 46 (22-79) | 46 (25-72) |
| Initial sites, no. (%) | ||
| Nasal cavity | 32 (67) | 27 (69) |
| Nasal cavity with adjacent structures | 16 (33) | 12 (31) |
| Ann Arbor stage, no. (%) | ||
| I | 36 (75) | 31 (80) |
| II | 2 (4) | 1 (2) |
| III | 0 (0) | 0 (0) |
| IV | 10 (21) | 7 (18) |
| ECOG score, no. (%) | ||
| 0 | 25 (52) | 23 (59) |
| 1 | 13 (27) | 8 (21) |
| 2 | 2 (4) | 2 (5) |
| 3 | 8 (17) | 6 (15) |
| LDH level, no. (%) | ||
| Normal | 34 (71) | 29 (74) |
| Elevated | 14 (29) | 10 (26) |
| IPI score, no. (%) | ||
| 0 | 22 (46) | 18 (47) |
| 1 | 9 (19) | 8 (20) |
| 2 | 9 (19) | 8 (20) |
| 3 | 5 (10) | 3 (8) |
| 4 | 3 (6) | 2 (5) |
| Survival, % | ||
| 5-y EFS rate | 39 | 41 |
| 5-y OS rate | 49 | 50 |
| Clinical features . | Entire group . | Subgroup . |
|---|---|---|
| No. of patients | 48 | 39 |
| No. male/no. female | 29/19 | 27/12 |
| Median age, y (range) | 46 (22-79) | 46 (25-72) |
| Initial sites, no. (%) | ||
| Nasal cavity | 32 (67) | 27 (69) |
| Nasal cavity with adjacent structures | 16 (33) | 12 (31) |
| Ann Arbor stage, no. (%) | ||
| I | 36 (75) | 31 (80) |
| II | 2 (4) | 1 (2) |
| III | 0 (0) | 0 (0) |
| IV | 10 (21) | 7 (18) |
| ECOG score, no. (%) | ||
| 0 | 25 (52) | 23 (59) |
| 1 | 13 (27) | 8 (21) |
| 2 | 2 (4) | 2 (5) |
| 3 | 8 (17) | 6 (15) |
| LDH level, no. (%) | ||
| Normal | 34 (71) | 29 (74) |
| Elevated | 14 (29) | 10 (26) |
| IPI score, no. (%) | ||
| 0 | 22 (46) | 18 (47) |
| 1 | 9 (19) | 8 (20) |
| 2 | 9 (19) | 8 (20) |
| 3 | 5 (10) | 3 (8) |
| 4 | 3 (6) | 2 (5) |
| Survival, % | ||
| 5-y EFS rate | 39 | 41 |
| 5-y OS rate | 49 | 50 |